Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Elena Santagostino, Shadan Lalezari, Mark T. Reding, Jonathan Ducore, Heng Joo Ng, Lone H. Poulsen, Lisa A. Michaels, Camila C.G. Linardi

Research output: Contribution to journalArticle

5 Scopus citations

Fingerprint Dive into the research topics of 'Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences